retatrutide dosing phase 2 trial isn't a GLP-1. It's not a dual agonist. It's a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon simultaneously. Three receptors. Three mechanisms. One protocol. Swipe to see what Let's talk about a new

This process involves starting with a lower dose and gradually increasing it over several weeks or months until the target therapeutic dose is reached

Stanley, B

The L-Cell Function L-cells perform several critical metabolic functions: GLP-1 Production: Convert proglucagon (precursor protein) into active GLP-1 hormone Nutrient Sensing: Detect proteins, fats, and carbohydrates passing through the intestine Gut-Brain Communication: Release peptide YY (PYY) that signals satiety to the brain Metabolic Regulation: Respond to short-chain fatty acids produced by gut bacteria Research demonstrates that L-cell density and function can be influenced by dietary patterns, gut microbiome composition, and specific nutrients

A 2022 randomized trial of exenatide did not meet its primary endpoint for reducing heavy drinking days in the overall population, though exploratory analyses suggested potential benefits in participants with obesity

Second, GLP-1 is like the speed bump in your gut